Article

Neurocognitive effects of kava (Piper methysticum): a systematic review.

Brain Sciences Institute, University of Technology, Melbourne, Victoria, Australia.
Human Psychopharmacology Clinical and Experimental (Impact Factor: 2.1). 03/2011; 26(2):102-11. DOI: 10.1002/hup.1180
Source: PubMed

ABSTRACT Kava (Piper methysticum) elicits dose-dependent psychotropic effects and thus may potentially deleteriously affect cognitive performance. Clinical trials have assessed the effects of kava on cognition, however, to our knowledge no systematic review has been conducted in this area.
To systematically review the effects of kava on cognition, providing an analysis of the individual study's methodological quality, results and effect sizes.
A systematic review was conducted of publications up to June 15th 2010, using the electronic databases MEDLINE, PsychINFO, CINAHL, Web of Science and The Cochrane Library. The search criteria involved kava and cognition related terms, e.g. memory and attention.
Ten human clinical trials met inclusion criteria (acute n = 7, chronic n = 3). One acute study found that kava significantly improved visual attention and working memory processes while another found that kava increased body sway. One chronic study found that kava significantly impaired visual attention during high-cognitive demand. Potential enhanced cognition may be attributed to the ability of kava to inhibit re-uptake of noradrenaline in the pre-frontal cortex, while increased body sway may be due to GABA pathway modulation.
The majority of evidence suggests that kava has no replicated significant negative effects on cognition.

0 Bookmarks
 · 
126 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Kava (Piper methysticum) is a plant-based medicine, which has been previously shown to reduce anxiety. To date, however, no placebo-controlled trial assessing kava in the treatment of generalized anxiety disorder (GAD) has been completed. A total of 75 participants with GAD and no comorbid mood disorder were enrolled in a 6-week double-blind trial of an aqueous extract of kava (120/240 mg of kavalactones per day depending on response) versus placebo. γ-Aminobutyric acid (GABA) and noradrenaline transporter polymorphisms were also analyzed as potential pharmacogenetic markers of response. Reduction in anxiety was measured using the Hamilton Anxiety Rating Scale (HAMA) as the primary outcome. Intention-to-treat analysis was performed on 58 participants who met inclusion criteria after an initial 1 week placebo run-in phase. Results revealed a significant reduction in anxiety for the kava group compared with the placebo group with a moderate effect size (P = 0.046, Cohen d = 0.62). Among participants with moderate to severe Diagnostic and Statistical Manual of Mental Disorders-diagnosed GAD, this effect was larger (P = 0.02; d = 0.82). At conclusion of the controlled phase, 26% of the kava group were classified as remitted (HAMA ≤ 7) compared with 6% of the placebo group (P = 0.04). Within the kava group, GABA transporter polymorphisms rs2601126 (P = 0.021) and rs2697153 (P = 0.046) were associated with HAMA reduction. Kava was well tolerated, and aside from more headaches reported in the kava group (P = 0.05), no other significant differences between groups occurred for any other adverse effects, nor for liver function tests. Standardized kava may be a moderately effective short-term option for the treatment of GAD. Furthermore, specific GABA transporter polymorphisms appear to potentially modify anxiolytic response to kava.
    Journal of clinical psychopharmacology 04/2013; · 5.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Bewohner der südpazifischen Inseln benutzen die Kavapflanze (Piper methysticum) traditionell zur Herstellung eines Getränks mit entspannender Wirkung. Seit den 1990er Jahren ist Kava auch in den westlichen Län-dern populär und wurde in Europa und Amerika als Arzneimittel vor allem in Tabletten-und Kapselform bei Angststörungen angewendet. Kava zeigt am Menschen angstlösende und schlafverbessernde Effekte, an Tieren konnten unter anderem sedieren-de, antikonvulsive und zentral muskelrelaxierende Wirkungen nachgewiesen werden, die auf Kavalac-tone als Hauptinhaltsstoffe von Kava zurückgeführt werden. Bereits im Jahre 2002 verlor Kava die Zulas-sung als Arzneimittel aufgrund nicht unerheblicher Nebenwirkungen, vor allem Leberschädigungen. Testbestellungen und Untersuchungen haben gezeigt, dass als Arzneimittel einzustufende Produkte mit pharmakologisch wirksamen Konzentrationen an Kavalactonen weiterhin über den Internethandel als vorgebliche Nahrungsergänzungsmittel illegal an den deutschen Verbraucher abgegeben werden. Die natürliche Herkunft wird werblich als Vorteil gegenüber synthetischen Tranquilizern hervorgeho-ben. Die kürzlich erfolgte Einstufung von Kava durch die International Agency for Research on Cancer (IARC) der WHO als ,,möglicherweise krebserregend für den Menschen'' (Gruppe 2B) verleiht einer verstärkten Kontrolle des Internethandels mit Kava-Produkten besonderen Nachdruck. Abstract The inhabitants of the South Pacific islands traditionally use the kava plant (Piper methysticum) for producing a beverage with relaxing effects. Since the 1990s, Kava is also popular in the western countries and has been used in Europe and America in tablet and capsule form to treat anxiety disorders. Kava exhibits anxiolytic and sleep-enhancing effects in humans. Re-search in experimental animals has proven sedative, anticonvulsant and central muscle relaxant effects, which may be caused by kavalactones as major con-stituents of kava. In 2002, kava has lost its authorisation as a medicinal product because of considerable side effects, particularly damage to the liver. Test purchases and analyses show that medicinal products containing pharmacologically active concentrations of kavalacto-nes are still sold over the internet to the German consumer as food supplements. The natural origin is highlighted as an advantage over synthetic tranquilizers. A high priority to control the internet market with kava products may arise from its recent evaluation as ''possibly carcinogenic to humans'' (Group 2B) by the WHO International Agency for Research on Cancer (IARC).
    Journal für Verbraucherschutz und Lebensmittelsicherheit 02/2014; 9(1):3-11. · 0.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anxiolytic kava products have been associated with rare but severe hepatotoxicity in humans. This adverse potential has never been captured in animal models and the responsible compound(s) remains to be determined. The lack of such knowledge greatly hinders the preparation of a safer kava product and limits its beneficial applications. In this study we evaluated the toxicity of kava as a single entity or in combination with acetaminophen (APAP) in C57BL/6 mice. Kava alone revealed no adverse effects for long-term usage even at a dose of 500 mg/kg bodyweight. On the contrary a three-day kava pre-treatment potentiated APAP-induced hepatotoxicity, resulted in an increase in serum ALT and AST and increased severity of liver lesions. Chalcone-based flavokawains A (FKA) and B (FKB) in kava recapitulated its hepatotoxic synergism with APAP while dihydromethysticin (DHM, a representative kavalactone and a potential lung cancer chemopreventive agent) had no such effect. These results, for the first time, demonstrate the hepatotoxic risk of kava and its chalcone-based FKA and FKB in vivo and suggest that herb-drug interaction may account for the rare hepatotoxicity associated with anxiolytic kava usage in humans.
    Chemical Research in Toxicology 09/2014; · 4.19 Impact Factor

Full-text

Download
193 Downloads
Available from
Jun 3, 2014